About
Technology
Issues
FAQ
Links
Official Page
Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.